Search Results
May 22, 2026, 02:00 ET Hugel highlights global vision for K-aesthetics
three major botulinum toxin markets — the U.S., China, and Europe," she said. "With a presence in more than 70 countries and strong manufacturing and R&D capabilities, Hugel has tremendous long-term growth potential. The company also benefits from being rooted in Korea, which has emerged as a global
More news about: Hugel
May 22, 2026, 01:45 ET Changan and Kawa achieve a significant milestone with a US$950 million investment and the launch of technologically innovative flexible fuel technology
achievement, Changan aims to leverage its extensive engine expertise to launch hybrid and electric models, further strengthening local supply chains and R&D capabilities. The company also plans to open more than 60 dealerships by 2026, continuing its global expansion and advancing smart and sustainable
More news about: Changan Group
May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
announced the preliminary PoC clinical study results for its global first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO)
More news about: Innovent Biologics
May 21, 2026, 22:40 ET 【2026 ASCO】亞盛醫藥公佈多項臨床進展，三項獲快速口頭報告
這項多中心、開放標簽的Ib期研究探索了奧雷巴替尼與貝林妥歐單抗聯合方案在復發/難治（R/R）Ph+ BCP-ALL或CML-LBP患者中的應用。入組時存在陽性可測量的殘留疾病（MRD）且非完全緩解（CR）的5例患者組中，4例達到CR，2例實現MRD轉陰，整體安全性可控。這項研究首次在國際患者群體中驗證了奧雷巴替尼聯合免疫療法在CML-LBP與R/R Ph+ BCP- ALL中的可行性。Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic
More news about: 亞盛醫藥
May 21, 2026, 20:05 ET 11 Greenberg Traurig Lawyers Recognized in 2026 Lawdragon 100 Leading Immigration Lawyers Guide
Dillon R. Colucci — Immigration, Individuals, Families, Business
More news about: Greenberg Traurig, LLP
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
NSCLC.About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major
More news about: Kelun-Biotech
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
announces updated data from the Phase 1 PoC clinical study of its first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the treatment of advanced immunotherapy(IO)-resistant non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical
More news about: Innovent Biologics
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
investigated as a next-generation B-cell maturation antigen (BCMA) x CD3 T-cell engager, as monotherapy in a cohort of heavily pre-treated BCMA-exposed R/R MM patients will be presented at the meeting.Etentamig is an investigational BCMA and CD3 bispecific antibody T-cell engager composed
More news about: AbbVie
May 21, 2026, 18:10 ET Crime organizado tem margem de lucro de até 500% com contrabando do Paraguai e movimenta R$ 60 bilhões por ano no Brasil, aponta estudo IDESF
content:https://www.prnewswire.com/br/comunicados-para-a-imprensa/crime-organizado-tem-margem-de-lucro-de-ate-500-com-contrabando-do-paraguai-e-movimenta-r-60-bilhoes-por-ano-no-brasil-aponta-estudo-idesf-302779624.htmlFONTE
More news about: IDESF (Instituto de Desenvolvimento Econômico e Social de Fronteiras)
May 21, 2026, 18:03 ET Coupa Acquires Tonkean to Accelerate Agentic Intake and Orchestration for Global Trade
guarantee compliance while maximizing adoption—all without any change management and no code. Founded in 2015, Tonkean is headquartered in Palo Alto with R&D in Tel Aviv. Tonkean investors include Foundation Capital, Magma, Lightspeed, and Accel.Logo -
More news about: Coupa Software
May 21, 2026, 17:45 ET Coupa Acquires Tonkean to Accelerate Agentic Intake and Orchestration for Global Trade
guarantee compliance while maximizing adoption—all without any change management and no code. Founded in 2015, Tonkean is headquartered in Palo Alto with R&D in Tel Aviv. Tonkean investors include Foundation Capital, Magma, Lightspeed, and Accel.
More news about: Coupa Software
May 21, 2026, 17:30 ET Rutgers Cancer Institute and RWJBarnabas Health to Highlight Advances Shaping the Future of Cancer Research at the 2026 ASCO Annual Meeting
Meeting, taking place May 29–June 2 in Chicago and online. Highlights include findings from a late-breaking abstract, Neo-adjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial, scheduled for presentation on June 1
More news about: Rutgers Cancer Institute and RWJBarnabas Health
May 21, 2026, 17:30 ET Canopy Studies Selected for Oral and Poster Presentations at 2026 ASCO Annual Meeting
Society of Hematology (ASH) Annual Meeting.3 Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring
More news about: Canopy
May 21, 2026, 17:23 ET Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
resistance to first-, second-, and third-generation ALK inhibitors, including tumors with single or compound treatment-emergent ALK mutations such as G1202R. In addition, neladalkib is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and
More news about: Nuvalent, Inc.
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
poster sessionReal-world data further supports the use of REZLIDHIA® (olutasidenib) in patients with R/R mIDH1 AML that have received prior venetoclaxSOUTH SAN FRANCISCO, Calif., May
More news about: Rigel Pharmaceuticals, Inc.
May 21, 2026, 17:00 ET Sapience Therapeutics Provides Positive Data Update from Phase 2 Trial of Lucicebtide Plus SOC in Patients with Glioblastoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
PMID: 38994023; PMCID: PMC11234274.4 Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005. DOI: 10.1056/NEJMoa043330.PMID: 157580095 Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields
More news about: Sapience Therapeutics, Inc.
May 21, 2026, 17:00 ET Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio
to offer targeted therapeutic solutions, particularly in rare cancers and neurological diseases, and invests nearly 20% of its brand-name sales in R&D.Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more
More news about: Servier Pharmaceuticals
May 21, 2026, 17:00 ET New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
China)Session Date & Time: Monday, June 1st, 2026, 8:00 AM-11:00 AM CDTT-Bren (BL-M07D1) in patients with recurrent or metastatic (R/M) ovarian cancer: Results from two phase II studiesTrial Reference: BL-M07D1-202/203 (NCT06031584/NCT06131450), China Session
More news about: SystImmune, Inc.
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval
More news about: Eli Lilly and Company
May 21, 2026, 16:54 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
very encouraged by these results and their implications for patients whose gout remains inadequately controlled," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. "These findings, including sustained urate lowering and a favourable efficacy and tolerability
More news about: Swedish Orphan Biotrauma AB
May 21, 2026, 16:51 ET Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout
very encouraged by these results and their implications for patients whose gout remains inadequately controlled," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi. "These findings, including sustained urate lowering and a favourable efficacy and tolerability
More news about: Swedish Orphan Biotrauma AB
May 21, 2026, 16:05 ET FLOWERS FOODS, INC. REPORTS FIRST QUARTER 2026 RESULTS
interruptions, intrusions, cyber-attacks or security breaches of such systems or risks associated with the implementation of the upgrade of our ERP system; and (r) the potential impact of climate change on the company, including physical and transition risks, our availability or restriction of resources, higher
More news about: Flowers Foods, Inc.
May 21, 2026, 15:49 ET Electrolux Group announces terms for the fully underwritten rights issue of SEK 9,062 million
https://news.cision.com/electrolux-group/r/electrolux-group-announces-terms-for-the-fully-underwritten-rights-issue-of-sek-9-062-million,c4351800The following files are available for download:
More news about: Electrolux Group
May 21, 2026, 15:45 ET Electrolux Group announces terms for the fully underwritten rights issue of SEK 9,062 million
https://news.cision.com/electrolux-group/r/electrolux-group-announces-terms-for-the-fully-underwritten-rights-issue-of-sek-9-062-million,c4351800The following files are available for download:
More news about: Electrolux Group